Concerning changes to the prescription drug monitoring program pursuant to the March 2021 audit report issued by the office of the state auditor.
2022 Regular Session
Health Care & Health Insurance
Legislative Audit Committee. Sections 1 and 2 of the bill clarify that each licensed health-care practitioner must query the prescription drug monitoring program (program) prior to filling a prescription for every opioid or benzodiazepine.Section 3 requires the group tasked with developing a strategic plan to reduce prescription drug misuse to also make recommendations to the executive director of the department of regulatory agencies concerning balancing the use of the program as a health-care tool with enforcement of the requirements of the program. (Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)
* Amendments passed in committee are not incorporated into the measure unless adopted by the full House or Senate.
** The status of Second Reading amendments may be subsequently affected by the adoption of an amendment to the Committee of the Whole Report. Refer to the House or Senate Journal for additional information.
Signed by the Speaker of the House
Signed by the President of the Senate
Senate Considered House Amendments - Result was to Concur - Repass
House Third Reading Passed - No Amendments
House Third Reading Laid Over Daily - No Amendments
House Second Reading Special Order - Passed with Amendments - Committee
House Committee on Health & Insurance Refer Amended to House Committee of the Whole
Introduced In House - Assigned to Health & Insurance
Senate Third Reading Passed - No Amendments
Senate Second Reading Passed - No Amendments
Senate Committee on Health & Human Services Refer Unamended - Consent Calendar to Senate Committee of the Whole
Introduced In Senate - Assigned to Health & Human Services